Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription


2 BJU Int
1 BMC Cancer
2 BMC Urol
1 Cancer Imaging
2 Eur Urol
1 Int J Radiat Oncol Biol Phys
3 Int J Urol
3 J Nucl Med
1 Oncogene
1 Oncol Rep
1 PLoS One
1 Proc Natl Acad Sci U S A
5 Prostate
1 Radiology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BJU Int

    Endpoint and control group in prostate cancer screening research: public health basics.
    BJU Int. 2024 Mar 29. doi: 10.1111/bju.16356.

    Response to 'Endpoint and control group in prostate cancer screening research: public health basics'.
    BJU Int. 2024 Mar 30. doi: 10.1111/bju.16357.

    BMC Cancer

  3. AYOUB HM, Zamzam ML, Elsemary EE, Hassanin IM, et al
    Correction: Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy.
    BMC Cancer. 2024;24:419.

    BMC Urol

  4. WU F, Huang F, Jiang N, Su J, et al
    Identification of ferroptosis related genes and pathways in prostate cancer cells under erastin exposure.
    BMC Urol. 2024;24:78.
    PubMed         Abstract available

  5. CHENG Y, Fan B, Fu Y, Yin H, et al
    Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram.
    BMC Urol. 2024;24:76.
    PubMed         Abstract available

    Cancer Imaging

  6. KOLADE OU, Brink A, Ayeni AO, More S, et al
    Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
    Cancer Imaging. 2024;24:46.
    PubMed         Abstract available

    Eur Urol

  7. ROY S, Fervaha G, Spratt DE, Sun Y, et al
    Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Eur Urol. 2024 Apr 2:S0302-2838(24)02239-5. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  8. ENGLMAN C, Maffei D, Allen C, Kirkham A, et al
    PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
    Eur Urol. 2024 Mar 30:S0302-2838(24)02232-2. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  9. MAITRE P, Maheshwari G, Sarkar J, Singh P, et al
    Late urinary toxicity and QOL with pelvic radiotherapy for high-risk prostate cancer: Dose-effect relations in the POP-RT randomized phase III trial.
    Int J Radiat Oncol Biol Phys. 2024 Mar 27:S0360-3016(24)00439.
    PubMed         Abstract available

    Int J Urol

  10. YAMAMOTO Y, Nonomura N
    Editorial Comment to Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
    Int J Urol. 2024 Apr 4. doi: 10.1111/iju.15458.

  11. URABE F, Sumiyoshi T, Tashiro K, Goto T, et al
    Prostate cancer and liquid biopsies: Clinical applications and challenges.
    Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15441.
    PubMed         Abstract available

  12. GOTO Y
    Editorial Comment on Prostate cancer and liquid biopsies: Clinical applications and challenges.
    Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15456.

    J Nucl Med

  13. SHI J, Li D, Chen M, Fu Y, et al
    The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
    J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
    PubMed         Abstract available

  14. HARDIANSYAH D, Yousefzadeh-Nowshahr E, Kind F, Beer AJ, et al
    Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [(177)Lu]Lu-PSMA-617 Therapy.
    J Nucl Med. 2024;65:566-572.
    PubMed         Abstract available

  15. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    PubMed         Abstract available


  16. CHEN M, Zou C, Tian Y, Li W, et al
    An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.
    Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03011.
    PubMed         Abstract available

    Oncol Rep

  17. HSIA YJ, Lin ZM, Zhang T, Chou TC, et al
    Butyrate increases methylglyoxal production through regulation of the JAK2/Stat3/Nrf2/Glo1 pathway in castration?resistant prostate cancer cells.
    Oncol Rep. 2024;51:71.
    PubMed         Abstract available

    PLoS One

  18. FONSECA-ALVES CE, Leis-Filho AF, Lacerda ZA, de Faria Lainetti P, et al
    Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
    PLoS One. 2024;19:e0297043.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  19. HE T, Cheng C, Qiao Y, Cho H, et al
    Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2322563121.
    PubMed         Abstract available


  20. GEBRAEL G, Hage Chehade C, Sayegh N, Tripathi N, et al
    Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24696.
    PubMed         Abstract available

  21. KIM J, Park S, Kim S, Ryu S, et al
    Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24700.
    PubMed         Abstract available

  22. KU HC, Cheng E, Cheng CF
    A body shape index (ABSI) but not body mass index (BMI) is associated with prostate cancer-specific mortality: Evidence from the US NHANES database.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24698.
    PubMed         Abstract available

  23. MODLIN IM, Kidd M, Drozdov IA, Boegemann M, et al
    Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.
    Prostate. 2024 Apr 3. doi: 10.1002/pros.24704.
    PubMed         Abstract available

  24. MARTELIN N, De Witt B, Chen B, Eschwege P, et al
    Development and validation of an imageless machine-learning algorithm for the initial screening of prostate cancer.
    Prostate. 2024 Apr 4. doi: 10.1002/pros.24703.
    PubMed         Abstract available


  25. JEWELL K, Hofman MS, Ong JSL, Levy S, et al
    Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy.
    Radiology. 2024;311:e231703.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.